7 research outputs found

    sj-docx-1-dhj-10.1177_20552076231207206 - Supplemental material for A mobile-based airway clearance care system using deep learning-based vision technology to support personalized home-based pulmonary rehabilitation for COAD patients: Development and usability testing

    No full text
    Supplemental material, sj-docx-1-dhj-10.1177_20552076231207206 for A mobile-based airway clearance care system using deep learning-based vision technology to support personalized home-based pulmonary rehabilitation for COAD patients: Development and usability testing by Jun-Ming Su, Kuan-Yuan Chen, Sheng-Ming Wu, Kang-Yun Lee and Shu-Chuan Ho in DIGITAL HEALTH</p

    The serum level of TGF-β1 in normal subjects and patients with bronchiectasis.

    No full text
    <p>The serum level of TGF-β1 in patients with bronchiectasis having at least one -1607G of <i>MMP-1</i> was measured and compared to different clinical setting. Individual difference was marked as p-values among different settings.</p

    HRCT grading system for patients with bronchiectasis.

    No full text
    <p>Each lobe of both lungs is graded for bronchiectatic changes on a scale of 0 to 3 (lingula was scored as a separate lobe), giving a maximum of 18 points. (A) Represents score 0: no bronchiectasis. (B) Represents score 1 in one lobe: one bronchopulmonary segment involved (C) Represents score 2 in one lobe: more than one bronchopulmonary segment involved. Total Score was 8 in this figure due to four lobes involved. (D) Represents score 3 in one lobe: grossly cystic bronchiectasis. Total Score was 12 in this figure due to three lobes involved.</p

    TGF-β1 levels secreted from monocytes under IL-1β stimulation for 48 hrs in normal subjects.

    No full text
    <p>PBMs were isolated from normal subjects, and stimulated with IL-1<b>β</b> (0, 2, 10 and 50 ng/ml alternatively) for 48 hours. Supernatants were collected and TGF-<b>β</b>1 level were measured. * denotes p<0.05, and ** denotes p<0.01 when compared to control in the 1G/2G genotype; and # denotes p<0.05 and ## denotes p<0.01 when compared to control in the 1G/1G genotype.</p

    Data_Sheet_1_Associations of the distance-saturation product and low-attenuation area percentage in pulmonary computed tomography with acute exacerbation in patients with chronic obstructive pulmonary disease.docx

    No full text
    BackgroundChronic obstructive pulmonary disease (COPD) has high global health concerns, and previous research proposed various indicators to predict mortality, such as the distance-saturation product (DSP), derived from the 6-min walk test (6MWT), and the low-attenuation area percentage (LAA%) in pulmonary computed tomographic images. However, the feasibility of using these indicators to evaluate the stability of COPD still remains to be investigated. Associations of the DSP and LAA% with other COPD-related clinical parameters are also unknown. This study, thus, aimed to explore these associations.MethodsThis retrospective study enrolled 111 patients with COPD from northern Taiwan. Individuals’ data we collected included results of a pulmonary function test (PFT), 6MWT, life quality survey [i.e., the modified Medical Research Council (mMRC) scale and COPD assessment test (CAT)], history of acute exacerbation of COPD (AECOPD), and LAA%. Next, the DSP was derived by the distance walked and the lowest oxygen saturation recorded during the 6MWT. In addition, the DSP and clinical phenotype grouping based on clinically significant outcomes by previous study approaches were employed for further investigation (i.e., DSP of 290 m%, LAA% of 20%, and AECOPD frequency of ≥1). Mean comparisons and linear and logistic regression models were utilized to explore associations among the assessed variables.ResultsThe low-DSP group (ConclusionA lower value of the DSP was related to a greater worsening of symptoms, more-frequent exacerbations, poorer pulmonary function, and more-severe emphysema (higher LAA%). These readily determined parameters, including the DSP and LAA%, can serve as indicators for assessing the COPD clinical course and may can serve as a guide to corresponding treatments.</p
    corecore